Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/27/21
End: 06/16/22
Due: 06/16/23
Phase: N/A
Priority: Normal
Start: 12/21/23
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma | NCT04956302 | Abdullah Khan | user2@example.com | None | 2021-09-27 | 2022-06-16 | 2023-06-16 | - | - | 2025-07-14 |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | NCT05981209 | Abdullah Khan | user2@example.com | None | 2023-12-21 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |